Welcome to our dedicated page for CollPlant Biotechnologies Ordinary Shares news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on CollPlant Biotechnologies Ordinary Shares stock.
CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is a pioneering company in regenerative and aesthetic medicine, specializing in the 3D bioprinting of tissues and organs and medical aesthetics. The company's core technology is its recombinant human collagen (rhCollagen), produced through proprietary plant-based genetic engineering. CollPlant's innovative products address diverse fields of tissue repair, aesthetics, and organ manufacturing, marking a new era in regenerative medicine.
CollPlant's flagship rhCollagen bioink product line is optimized for 3D bioprinting applications, including drug discovery, tissue testing, and the development of transplantable tissues and organs. The company's unique Vergenix™ line includes a soft tissue repair matrix for tendinopathy treatment and a wound repair matrix that promotes rapid healing of acute and chronic wounds.
In the medical aesthetics market, CollPlant is advancing its regenerative breast implants and dermal fillers. The company has formed strategic partnerships, including a notable collaboration with AbbVie for the development of dermal and soft tissue fillers, triggering milestone payments and potential future royalties.
Recent achievements include the initiation of pre-clinical trials for regenerative breast implants and progress in large-animal studies demonstrating tissue regeneration and safety. In addition, CollPlant's advanced bioinks are facilitating the bio-fabrication of human tissues and organs in collaboration with industry leaders.
Financially, CollPlant reported significant revenue increases due to milestone payments and product sales, although it continues to invest in research and development to maintain its leading position in the market. The company's cash and cash equivalents provide a robust runway for at least two years of operation, supporting ongoing and future projects.
CollPlant's commitment to sustainability is reflected in its plant-based production process and adherence to Environmental, Social, and Governance (ESG) principles. The company joined the United Nations Global Compact to further its sustainable corporate governance goals.
CollPlant Biotechnologies (NASDAQ: CLGN) reported Q3 2024 financial results, highlighting promising developments in its regenerative breast implant program. The company achieved significant implant vascularization and rapid native tissue ingrowth in pre-clinical trials with 200cc commercial-sized implants. Q3 revenues were $4,000 compared to $43,000 in Q3 2023. Net loss was $4.3 million ($0.38 per share). Cash position stood at $15.4 million as of September 30, 2024, providing runway until end of 2025. The company is prioritizing non-dilutive funding through new collaborations while maintaining its ongoing partnership with AbbVie for dermal filler development.
CollPlant Biotechnologies (NASDAQ: CLGN) has announced it will release its third quarter 2024 financial results on Wednesday, November 27, 2024, before U.S. markets open. The company will host a conference call and webcast at 10:00 a.m. EST on the same day to discuss the results and provide corporate updates. Investors can participate via phone or through a live webcast available on the company's investor relations website. Questions for management can be submitted in advance via email.
CollPlant Biotechnologies (NASDAQ: CLGN) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Initiated pre-clinical trial with 200cc rhCollagen-based regenerative breast implants printed with Stratasys' Origin® 3D printer
- Breast implants could address a $3.0 billion market opportunity
- Q2 revenues were $249,000, down from $10.2 million in Q2 2023 due to a one-time milestone payment in the prior year
- Q2 GAAP net loss was $4.2 million or $0.37 per share
- Cash and cash equivalents of $18.9 million as of June 30, 2024
- Cash runway expected to last until at least the end of 2025
The company is advancing its regenerative breast implant program and released its first ESG report. CollPlant aims to lead in regenerative medicine with its innovative collagen technology.
CollPlant Biotechnologies (Nasdaq: CLGN) and Stratasys (Nasdaq: SSYS) have initiated a pre-clinical study for 3D-printed regenerative breast implants. The study focuses on 200cc commercial-sized implants produced using CollPlant's rhCollagen-based bioinks on a Stratasys Origin® printer. The innovative implants aim to promote natural breast tissue growth and completely degrade over time, potentially revolutionizing both reconstructive and aesthetic procedures in the $3 billion breast implant market.
The collaboration leverages Stratasys' 3D printing expertise and CollPlant's regenerative medicine technology. Initial results are expected in the first half of 2025. Previous pre-clinical studies have shown promising results, including neovascularization and tissue regeneration without adverse reactions.
CollPlant Biotechnologies (CLGN) and Stratasys (SSYS) have initiated a pre-clinical study for 3D-printed regenerative breast implants. The 200cc commercial-sized implants, made using CollPlant's rhCollagen-based bioinks and printed on a Stratasys Origin® printer, aim to promote natural breast tissue growth and completely degrade over time. This innovation targets the $3 billion breast implant market, offering a potential alternative to traditional silicone implants and autologous fat transfer procedures.
The collaboration focuses on developing a bioprinting solution and scaling up the fabrication process. Initial results from the study are expected in the first half of 2025. Previous pre-clinical studies have shown promising results, including neovascularization and tissue regeneration without adverse reactions.
CollPlant Biotechnologies (Nasdaq: CLGN), a leader in regenerative and aesthetics medicine, has announced its upcoming financial report and conference call for the second quarter of 2024. The company, known for its innovative non-animal-derived collagen technologies, will release its financial statements on Tuesday, August 20, 2024, before U.S. markets open.
A conference call and webcast are scheduled for 10:00 a.m. EDT on the same day. Investors can participate using various dial-in numbers based on their location. A live webcast will also be available in listen-only mode. To streamline the process, CollPlant offers a Call me™ feature for easy access. Investors can submit questions in advance by emailing Dan Ferry at LifeSci Advisors
CollPlant Biotechnologies (Nasdaq: CLGN) has released its first Environmental, Social and Corporate Governance (ESG) and Sustainability Report for 2023. The report outlines the company's initiatives to adopt an ESG strategy focused on high-impact areas. CollPlant aims to enhance plant-based production, reduce emissions, and deliver safe medical solutions.
The strategy is built on three pillars: Impact on the Planet, Impact on People, and Impact on Business Conduct. CollPlant's innovative rhCollagen technology eliminates the need for animal-derived collagen, promoting more ethical and sustainable practices. The company is committed to accelerating the transition to a low-carbon footprint world and enhancing its corporate ESG practices.
CEO Yehiel Tal emphasized that CollPlant's overall strategy is driven by its vision to lead in regenerative medicine and improve global health with its collagen technology. The report serves as a foundation for sharing the company's journey, ambitions, and steps towards a sustainable future in regenerative and aesthetic medicine.
CollPlant Biotechnologies (Nasdaq: CLGN) announced a major milestone with the successful bio-printing of 200cc commercial-size regenerative breast implants using its proprietary rhCollagen bioinks. The company also reported positive interim pre-clinical data from ongoing large-animal studies, showing promising tissue growth and neovascularization without adverse reactions. The implants are designed to regenerate breast tissue, potentially offering a safer alternative to synthetic silicone implants. Large-animal studies are ongoing, with results expected in Q4 2024 and Q1 2025, which will support future human trials and commercialization.
CollPlant Biotechnologies (Nasdaq: CLGN) reported its Q1 2024 financial results and provided a corporate update. The company initiated a new large-animal study for its 3D-bioprinted breast implants in December 2023, expected to conclude in June 2024. Q1 2024 GAAP revenue was $98,000, a decrease from $433,000 in Q1 2023. Costs of revenue increased to $545,000 from $325,000, resulting in a gross loss of $447,000 compared to a gross profit of $108,000 in Q1 2023. Net loss widened to $4.2 million from $3.7 million. The company also highlighted advancements in its Environmental, Social, and Governance (ESG) initiatives and recent patent approvals in the U.S., Brazil, Israel, and Australia. Cash and cash equivalents as of March 31, 2024, stood at $23.2 million.
CollPlant Biotechnologies (Nasdaq: CLGN) announced the release of its financial results for the first quarter of 2024 on May 29, 2024, before U.S. market opening. The company will host a conference call and webcast the same day at 10:00 a.m. EDT to discuss these results and provide corporate updates.
U.S. investors can dial 1-877-407-9716, international investors can call 1-201-493-6779, and Israeli investors can dial 1-809-406-247 using Conference ID 13745964. Participants can avoid long wait times by using the Call me™ feature available 15 minutes prior to the call.
A live listen-only webcast will be available, with a replay accessible on the company's website for a period. Questions for management can be submitted via email to Dan Ferry at LifeSci Advisors up to 24 hours before the event.
FAQ
What is the current stock price of CollPlant Biotechnologies Ordinary Shares (CLGN)?
What is the market cap of CollPlant Biotechnologies Ordinary Shares (CLGN)?
What does CollPlant Biotechnologies Ltd do?
What is rhCollagen?
What are CollPlant's main products?
What are the recent achievements of CollPlant?
Who are CollPlant's strategic partners?
Where does CollPlant operate?
What are CollPlant's financial highlights?
How is CollPlant contributing to sustainability?
What is the market potential for CollPlant's products?
How can investors participate in CollPlant's conference calls?
